Triple-Drug attack shows promise against tough prostate cancer

NCT ID NCT04946370

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. It tests whether adding a targeted radiation drug (225Ac-J591) to immunotherapy (pembrolizumab) and an androgen-receptor inhibitor works better than the immunotherapy and hormone drug alone. The goal is to shrink tumors, lower PSA levels, and improve survival. About 52 men will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Columbia University Irving Cancer Center
RECRUITING

New York, New York, 10032, United States
Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
New York Presbyterian/Brooklyn Methodist Hospital
RECRUITING

Brooklyn, New York, 11215, United States
New York Presbyterian/Weill Cornell Medical Center
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.